Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Express Scripts
Colorcon
Mallinckrodt
Harvard Business School

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SEROMYCIN

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Seromycin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00182000 Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy Completed Hartford Hospital Phase 3 2003-11-01 This study will assess the effectiveness of Seromycin (D-cycloserine) in enhancing the positive effects of behavior therapy for people with Obsessive-Compulsive Disorder (OCD).
NCT00182000 Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy Completed Massachusetts General Hospital Phase 3 2003-11-01 This study will assess the effectiveness of Seromycin (D-cycloserine) in enhancing the positive effects of behavior therapy for people with Obsessive-Compulsive Disorder (OCD).
NCT00198120 Safety and Effectiveness of D-Cycloserine in Children With Autism Completed Indiana University School of Medicine Phase 3 2004-02-01 This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.
NCT00198120 Safety and Effectiveness of D-Cycloserine in Children With Autism Completed National Alliance for Research on Schizophrenia and Depression Phase 3 2004-02-01 This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.
NCT00198120 Safety and Effectiveness of D-Cycloserine in Children With Autism Completed National Institute of Mental Health (NIMH) Phase 3 2004-02-01 This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.
NCT00198120 Safety and Effectiveness of D-Cycloserine in Children With Autism Completed Indiana University Phase 3 2004-02-01 This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.
NCT00408031 D-cycloserine for Major Depressive Disorder Completed National Alliance for Research on Schizophrenia and Depression Phase 2 2007-01-01 For many depression patients treatment changes are required, including switching to another antidepressant and addition of a second antidepressant or a non-antidepressant agent ("augmentation"). The need to modify treatment is usually necessary because of partial or no response to first-line monotherapy or the failure to achieve remission although treatment response (improvement) has been obtained. These caveats of presently available antidepressant drugs highlight the need for innovative pharmacological treatment strategies. Recent data suggest that N-methyl-D-aspartate receptor (NMDAR) antagonists and partial agonists at the NMDAR-associated glycine binding site may represent a novel type of antidepressant medications. These types of compounds protect vulnerable neurons against a variety of insults, including stress-induced damage, and may serve to enhance and maintain normal synaptic connectivity. In animal models, these compounds mimic the effects of clinically effective antidepressants. Furthermore, down-regulation of the glycine site of the NMDAR was found to be a common feature of currently used antidepressant medications. D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis, that acts as a partial agonist at the NMDAR-associated glycine site. Beneficial antidepressant effects have been reported with 500-1000 mg/day DCS regimens in depressed tuberculosis patients and recent preliminary findings suggest that DCS may also be beneficial in the treatment of major depressive disorder. The antidepressant effects of DCS seem to reflect consequences of its capacity to reduce NMDAR receptor function. In the present project, it is proposed to assess, using a random assignment, parallel-group, double blind, placebo controlled design, the effects of a NMDAR -antagonist DCS dose regimen, 250 --> 1000 mg/day for 6 wks, as adjuvant pharmacotherapy for treatment-resistant major depressive disorder patients. The study methodology includes the assessment of DCS effects upon symptoms profile, neurocognitive tests performance, amino acids serum levels, and brain electrophysiology parameters associated with the prepulse inhibition-startle response paradigm. It is hypothesized that significant beneficial DCS treatment effects will be registered.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Seromycin

Condition Name

Condition Name for Seromycin
Intervention Trials
Schizophrenia 3
Obsessive-Compulsive Disorder 3
Major Depressive Disorder 2
Posttraumatic Stress Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Seromycin
Intervention Trials
Disease 7
Depression 4
Depressive Disorder 4
Stress Disorders, Traumatic 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Seromycin

Trials by Country

Trials by Country for Seromycin
Location Trials
United States 24
Canada 3
Israel 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Seromycin
Location Trials
Massachusetts 5
Texas 2
Florida 2
New York 2
Indiana 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Seromycin

Clinical Trial Phase

Clinical Trial Phase for Seromycin
Clinical Trial Phase Trials
Phase 4 7
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Seromycin
Clinical Trial Phase Trials
Completed 14
Recruiting 4
Unknown status 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Seromycin

Sponsor Name

Sponsor Name for Seromycin
Sponsor Trials
Massachusetts General Hospital 5
National Institute of Mental Health (NIMH) 5
National Alliance for Research on Schizophrenia and Depression 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Seromycin
Sponsor Trials
Other 38
NIH 9
Industry 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
AstraZeneca
Johnson and Johnson
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.